Calithera Biosciences Price Pattern Analysis
| CALA Pink Sheet | USD 0.0001 -0.0002 -66.67% |
Momentum
OversoldOverbought
38 · Sell Extended
Attention data alongside price movement for Calithera Biosciences reveals how sensitive the stock is to headlines. Relative attention metrics help frame Calithera Biosciences' position within its peer group.
Calithera Biosciences Current Signal Summary
Calithera Biosciences's momentum reading (RSI at 38) sits in bearish territory, while the expected daily return of 6.35% is positive. Daily volatility at 47.75% is elevated, widening the range of near-term outcomes. Overall, signals for Calithera Biosciences are mixed — expected returns are positive but momentum is weak, suggesting a potential turning point.
Attention patterns around Calithera Biosciences reveal how closely headline activity correlates with price direction. Volatility and risk context alongside sentiment data helps assess whether attention is a leading indicator.
Calithera Biosciences Post-Event Predicted Price | $ 8.6E-5 |
Sentiment data is most useful when read with forecasting, technical, and analyst context. Earnings data and momentum signals add quantitative depth to the sentiment picture.
Statistical evidence for mean reversion in Calithera Biosciences' appears through its tendency to revert after extreme valuations. Under mean reversion theory, Calithera Biosciences' price extremes are viewed as temporary dislocations that may self-correct. Mean reversion in Calithera Biosciences' is often observed around historical valuation multiples. Historical data for Calithera Biosciences shows that extreme valuations have tended to normalize over multi-year periods.
Post-Sentiment Price Density Analysis
The probability distribution for Calithera Biosciences' predicted price encodes the full spectrum of outcomes by estimated likelihood. Confidence intervals from Calithera Biosciences' distribution widen as the forecast horizon extends, reflecting compounding uncertainty. Comparing the width of Calithera Biosciences' upside distribution against the downside reveals the risk-reward asymmetry for Calithera Biosciences. Calithera Biosciences' predicted outcome range provides a realistic frame for what the model considers plausible for Calithera Biosciences.
Next price density |
| Expected price to next headline |
Estimated Post-Sentiment Price Volatility
After analyzing Calithera Biosciences' historical price reactions to major news, we derive upside and downside boundaries for Calithera Biosciences. Calithera Biosciences' post-sentiment downside and upside margins for the prediction period are 0.00 and 47.75, respectively. This analysis complements technical and fundamental research by adding a news dimension to Calithera Biosciences' forecasting.
Current Value
This after-hype projection for Calithera Biosciences uses a 3 months horizon to examine how price may behave after short-term sentiment effects dissipate. The after-hype estimate is most informative when comparing sentiment-driven price extension with a more measured post-news scenario.
Price Outlook Analysis
When Calithera Biosciences' price jumps with no clear reason, knowing the role of market sentiment matters a lot. Much of a stock's price move comes from press news that has nothing to do with real earnings. Price momentum in Calithera Biosciences that lacks fundamental backing tends to be fragile and susceptible to sharp reversal.
| Expected Return | Period Volatility | Sentiment Sensitivity | Peer Sensitivity | News Density | Peer Density | Next Expected Sentiment |
6.35 | 47.75 | 0.00 | 0.00 | 0 Events | 0 Events | In 5 to 10 days |
| Latest Traded Price | Expected Post-Event Price | Potential Return on Next Event | Post-Sentiment Volatility | |
0.0001 | 0.000086 | 13.61 |
|
Market Sentiment Timeline
Calithera Biosciences is currently traded for 0.0001. Calithera Biosciences's price shows low sensitivity to headline-driven sentiment. is expected to decline in value after the next headline, with the price expected to drop to 8.6E-5. The average volatility of media hype impact on CALA price is insignificant. The price decrease on the next news stands at -13.61%, whereas the daily expected return is currently at 6.35%. The volatility of peer sentiment impact on Calithera Biosciences is about 0.0%, with the expected peer-implied price after the next announcement near 0.00. About 27.0% of CALA shares are held by institutions such as insurance companies. CALA has price-to-book (P/B) ratio of 1.86. Equities trading at this Price to Book (P/B) range reflect investor confidence in earnings power beyond book value. Calithera Biosciences reported a loss per share of 1.59. CALA had not issued any dividends in recent years. The firm completed a 0.050-for-1 stock split on 15th of June 2022. Given a 90-day horizon, the next expected press release will be in 5 to 10 days. Calithera Biosciences Basic Forecasting Models places Calithera Biosciences' projections alongside historical fundamentals.Related Market Sentiment Analysis
The comparative sentiment analysis table for Calithera Biosciences provides risk metrics for Calithera Biosciences' direct competitors. Value-at-risk and maximum drawdown for Calithera Biosciences' competitors provide context for assessing Calithera Biosciences's relative risk. Analyzing how Calithera Biosciences' sector peers have historically reacted to news helps model sentiment dynamics around Calithera Biosciences. The peer comparison framework for Calithera Biosciences makes it possible to benchmark Calithera Biosciences' news sensitivity against direct competitors.
| SentimentElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| IVBT | Innovation1 Biotech | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| TLOG | TetraLogic Pharmaceuticals Corp | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ARNI | Arno Therapeutics | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| TNGNQ | Tengion | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| BXRXQ | Baudax Bio | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| BTTX | Better Therapeutics | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| KLDO | Kaleido Biosciences | 0.00 | 0 per month | 0.00 | 0.10 | 0.00 | 0.00 | 583.33 | |
| PANC | Panacos Pharmaceuticals | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SCIE | Spectrascience New | 0.00 | 0 per month | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| ONPH | Oncology Pharma | 0.00 | 0 per month | 16.34 | 0.26 | 96.08 | -36.25 | 202.12 |
Calithera Biosciences Additional Predictive Modules
Calithera Biosciences predictive analysis applies quantitative techniques to historical price data, aiming to identify conditions that have preceded similar moves in the past. No prediction model eliminates uncertainty; the goal is to identify scenarios with favorable risk-adjusted probabilities.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Sentiment Indicators & Methodology
Sentiment analysis for Calithera Biosciences evaluates news tone, positioning, and narrative momentum. Tone dispersion can increase uncertainty and volatility clustering. Calithera Biosciences has a market cap of 341,075, ROE of -114.14%.
Calithera Biosciences analytics rely on periodic company reporting and market reference feeds, with quality checks and normalization applied.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board